Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × Pharmacogenomic Variants × Clear all
NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 13 charts
Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡